近日,，國(guó)際學(xué)術(shù)期刊Journal  of  Cellular  and  Molecular  Medicine發(fā)表了中科院營(yíng)養(yǎng)所關(guān)于青蒿素及其衍生物抗癌研究的最新發(fā)現(xiàn)文章。

在王慧研究員的指導(dǎo)下，博士生陳濤通過(guò)腫瘤細(xì)胞系和動(dòng)物模型,，系統(tǒng)研究了青蒿素及其主要衍生物對(duì)卵巢癌的潛在抗癌活性以及構(gòu)效關(guān)系,，并探討了相關(guān)分子機(jī)制,。研究表明,，雙氫青蒿素(Dihydroartemisinin)在該類化合物中活性較強(qiáng)，能有效的抑制卵巢癌的生長(zhǎng),，其抗癌機(jī)制是通過(guò)“死亡受體以及線粒體介導(dǎo)的-Caspases依賴性”凋亡信號(hào)途徑來(lái)實(shí)現(xiàn)的；同時(shí)雙氫青蒿素可以作為化療藥物增敏劑,，明顯提高卵巢癌一線化療藥卡鉑(Carboplatin)的療效,。該研究為青蒿素類化合物作為新型抗癌(輔助)藥物用于臨床研究提供了重要的實(shí)驗(yàn)依據(jù)。（生物谷Bioon.com）

生物谷推薦原始出處：

Journal of cellular and molecular medicine, 2008 May 2

Dihydroartemisinin Induces Apoptosis and Sensitizes Human Ovarian Cancer Cells to Carboplatin Therapy.

Chen T, Li M, Zhang R, and Wang H

The present study was designed to determine the effects of artemisinin and its derivatives on human ovarian cancer cells, to evaluate their potential as novel chemotherapeutic agents used alone or in combination with a conventional cancer chemotherapeutic agent, and to investigate their underlying mechanisms of action. Human ovarian cancer cells (A2780 and OVCAR-3), and Immortalized non-tumorigenic human Ovarian Surface Epithelial cells (IOSE144), were exposed to four artemisinin compounds for cytotoxicity testing. The in vitro and in vivo antitumor effects and possible underlying mechanisms of action of dihydroartemisinin, the most effective compound, were further determined in ovarian cancer cells. Artemisinin compounds exerted potent cytotoxicity to human ovarian carcinoma cells, with minimal effects on non-tumorigenic OSE cells. Dihydroartemisinin inhibited ovarian cancer cell growth when administered alone or in combination with carboplatin, presumably through the death receptor- and, mitochondrion-mediated caspase-dependent apoptotic pathway. These effects were also observed in in vivo ovarian A2780 and OVCAR-3 xenograft tumor models. In conclusion, artemisinin derivatives, particularly dihydroartemisinin, exhibit significant anticancer activity against ovarian cancer cells in vitro and in vivo, with minimal toxicity to non-tumorigenic human OSE cells, indicating that they may be promising therapeutic agents for ovarian cancer, either used alone or in combination with conventional chemotherapy.